{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-029456","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.826897+00:00","generated_at":"2026-06-22T00:25:00.124139+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arrowhead sells olpasiran royalty rights to Royalty Pharma for up to $410M","bullets":["Royalty Pharma pays $250M upfront for future royalties from Amgen on olpasiran.","Up to $160M in milestones: $50M on Phase 3 enrollment, $50M on FDA approval, $60M after annual royalty receipt threshold.","Arrowhead retains eligibility for all milestone payments from Amgen under the original license agreement.","Transaction provides non-dilutive cash to fund Arrowhead's pipeline and operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-029456","json":"https://secwatch.observer/filing/0001628280-22-029456.json","markdown":"https://secwatch.observer/filing/0001628280-22-029456.md","text":"https://secwatch.observer/filing/0001628280-22-029456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828022029456/0001628280-22-029456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828022029456/arwr-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:25:00.124139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a73d4ea4b7f4dacac239a3d0bbad210382e1d83","claim":"ARROWHEAD PHARMACEUTICALS, INC. entered into Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at up to $410 million (effective 2022-11-09).","evidence_excerpt":"Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into a Royalty Purchase Agreement (the “Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”), pursuant to which Royalty Pharma agreed to pay up to $410 million in cash to the Company","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828022029456/0001628280-22-029456-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Royalty Pharma Investments 2019 ICAV"},{"label":"Value","value":"up to $410 million"},{"label":"Effective","value":"2022-11-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}